Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04665115
Title Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Waldenstroem's macroglobulinemia

mantle cell lymphoma

marginal zone B-cell lymphoma

Therapies

Ibrutinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.